drugset

drugset / Trial / NCT06941350

A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD

NCT06941350 ↗

Phase 1/2 Not yet recruiting 24 enrolled Nuwacell Biotechnologies Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

Evaluate the safety and efficacy of NCR102 injection in the treatment of SR-aGVHD patients who have failed second-line therapy.

Timeline

Start: 2025-04-28
Primary completion: 2026-10-30
Completion: 2027-05-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NCR102	Unknown	—	—

Indications